Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.

MLA

Lu, Yang, et al. “Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab.” Cancer Research, vol. 67, no. 17, Sept. 2007, pp. 8240–47. EBSCOhost, https://doi.org/10.1158/0008-5472.CAN-07-0589.

APA

Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., Mendelsohn, J., & Fan, Z. (2007). Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Research, 67(17), 8240–8247. https://doi.org/10.1158/0008-5472.CAN-07-0589

Chicago

Lu, Yang, Xinqun Li, Ke Liang, Rodney Luwor, Zahid H Siddik, Gordon B Mills, John Mendelsohn, and Zhen Fan. 2007. “Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab.” Cancer Research 67 (17): 8240–47. doi:10.1158/0008-5472.CAN-07-0589.